Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives
| Autor: | Bharati Kochar, Wenli Chen, Yue Jiang, Millie D. Long, Yuting Bu, Edward L. Barnes |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Crohn’s disease
safety medicine.medical_specialty home infusion Population AcademicSubjects/MED00972 Vedolizumab inflammatory bowel disease Internal medicine Patient experience medicine AcademicSubjects/MED00760 education AcademicSubjects/MED00260 ulcerative colitis therapy Crohn's disease education.field_of_study treatment business.industry home health services Gastroenterology Retrospective cohort study Odds ratio medicine.disease Infliximab Observations and Research Cohort business medicine.drug |
| Zdroj: | Crohn's & Colitis 360 |
| ISSN: | 2631-827X |
| DOI: | 10.1093/crocol/otab063 |
| Popis: | Background Home infusions (HIs) for biologic medications are an option for inflammatory bowel disease (IBD) patients in the United States. We aimed to describe the population receiving HIs and report patient experience with HIs. Methods We conducted a retrospective cohort study in the Quintiles-IMSLegacy PharMetrics Adjudicated Claims Database from 2010 to 2016 to describe the population receiving infliximab (IFX) and vedolizumab (VDZ) HIs and determine predictors for an urgent/emergent visit post-HIs. We then administered a cross-sectional survey to IBD Partners Internet-based cohort participants to assess knowledge and experience with infusions. Results We identified claims for 11 892 conventional IFX patients, 1573 home IFX patients, 438 conventional VDZ patients, and 138 home VDZ patients. There were no differences in demographics or median charges with IFX home and conventional infusions. Home VDZ infusions had a greater median charge than conventional VDZ infusion. Less than 4% of patients had an urgent/emergent visit post-HIs. Charlson comorbidity index > 0 (odds ratio [OR]: 1.95; 95% confidence interval [CI], 1.01-3.77) and Medicaid (OR: 3.01; 95% CI, 1.53-5.94) conferred significantly higher odds of urgent/emergent visit post-HIs. In IBD Partners, 644 IBD patients responded; 56 received HIs. The majority chose HIs to save time and preferred HIs to conventional infusions. Only 2 patients reported an urgent/emergent visit for HI-related problems. Conclusions HI appears to be safe in IBD patients receiving IFX and VDZ. However, patients with fewer resources and more comorbidities are at increased risk for an urgent/emergent visit post-HIs. The overall patient experience with HI is positive. Expansion of HIs may result in decreased therapy-related logistic burden for carefully selected patients. Lay Summary Inflammatory bowel disease patients receiving home biologic infusions did not have a greater risk for needing emergent care after their infusion compared with patients receiving healthcare facility-based infusions. Separately, we surveyed patients receiving home infusions and they reported positive experiences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|